 Source: ra2 studioShutterstock Shares of Fate Therapeutics NASDAQ: FATE stock are up 3 following a massive purchase by two of Cathie Woods exchange-traded funds ETFs. Fate is a clinical stage biotechnology company that develops cellular immunotherapies for patients with cancer and immune disorders. 